Selected research
Industry Research
Intravenous Injection Immunoglobulin Industry Research Report 2026
Market perspective
The global Intravenous Injection Immunoglobulin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Intravenous Injection Immunoglobulin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Intravenous Injection Immunoglobulin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Intravenous Injection Immunoglobulin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Intravenous Injection Immunoglobulin include Boya-Bio, CTBB, Sinopharm, Beijing Tiantan Biological Products, Guangdong Shuagnlin Bio-pharmacy, Hualan Bio, Nanyue Biopharming, Shanghai RAAS and Weiguang Biological, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Intravenous Injection Immunoglobulin market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Intravenous Injection Immunoglobulin Market by Company
Boya-Bio
CTBB
Sinopharm
Beijing Tiantan Biological Products
Guangdong Shuagnlin Bio-pharmacy
Hualan Bio
Nanyue Biopharming
Shanghai RAAS
Weiguang Biological
Intravenous Injection Immunoglobulin Segment by Type
5g/100ml
2.5g/50ml
1g/20ml
10g/200ml
1.25g/25ml
Intravenous Injection Immunoglobulin Segment by Application
Hospital
Clinic
Others
Intravenous Injection Immunoglobulin Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Injection Immunoglobulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intravenous Injection Immunoglobulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Injection Immunoglobulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Intravenous Injection Immunoglobulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Intravenous Injection Immunoglobulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Intravenous Injection Immunoglobulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 5g/100ml
- 2.5g/50ml
- 1g/20ml
- 10g/200ml
- 1.25g/25ml
Applications
- Hospital
- Clinic
- Others
Companies covered
- Boya-Bio
- CTBB
- Sinopharm
- Beijing Tiantan Biological Products
- Guangdong Shuagnlin Bio-pharmacy
- Hualan Bio
- Nanyue Biopharming
- Shanghai RAAS
- Weiguang Biological
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Intravenous Injection Immunoglobulin Market Size (2021-2032)
- 2.2.2 Global Intravenous Injection Immunoglobulin Sales (2021-2032)
- 2.2.3 Global Intravenous Injection Immunoglobulin Market Average Price (2021-2032)
- 2.3 Intravenous Injection Immunoglobulin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 5g/100ml
- 2.3.3 2.5g/50ml
- 2.3.4 1g/20ml
- 2.3.5 10g/200ml
- 2.3.6 1.25g/25ml
- 2.4 Intravenous Injection Immunoglobulin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Intravenous Injection Immunoglobulin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Intravenous Injection Immunoglobulin Sales (L) of Manufacturers (2021-2026)
- 3.3 Global Intravenous Injection Immunoglobulin Revenue of Manufacturers (2021-2026)
- 3.4 Global Intravenous Injection Immunoglobulin Average Price by Manufacturers (2021-2026)
- 3.5 Global Intravenous Injection Immunoglobulin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Intravenous Injection Immunoglobulin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Intravenous Injection Immunoglobulin, Product Type & Application
- 3.8 Global Manufacturers of Intravenous Injection Immunoglobulin, Established Date
- 3.9 Global Intravenous Injection Immunoglobulin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boya-Bio
- 4.1.1 Boya-Bio Company Information
- 4.1.2 Boya-Bio Business Overview
- 4.1.3 Boya-Bio Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boya-Bio Intravenous Injection Immunoglobulin Product Portfolio
- 4.1.5 Boya-Bio Recent Developments
- 4.2 CTBB
- 4.2.1 CTBB Company Information
- 4.2.2 CTBB Business Overview
- 4.2.3 CTBB Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CTBB Intravenous Injection Immunoglobulin Product Portfolio
- 4.2.5 CTBB Recent Developments
- 4.3 Sinopharm
- 4.3.1 Sinopharm Company Information
- 4.3.2 Sinopharm Business Overview
- 4.3.3 Sinopharm Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sinopharm Intravenous Injection Immunoglobulin Product Portfolio
- 4.3.5 Sinopharm Recent Developments
- 4.4 Beijing Tiantan Biological Products
- 4.4.1 Beijing Tiantan Biological Products Company Information
- 4.4.2 Beijing Tiantan Biological Products Business Overview
- 4.4.3 Beijing Tiantan Biological Products Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Beijing Tiantan Biological Products Intravenous Injection Immunoglobulin Product Portfolio
- 4.4.5 Beijing Tiantan Biological Products Recent Developments
- 4.5 Guangdong Shuagnlin Bio-pharmacy
- 4.5.1 Guangdong Shuagnlin Bio-pharmacy Company Information
- 4.5.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
- 4.5.3 Guangdong Shuagnlin Bio-pharmacy Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Guangdong Shuagnlin Bio-pharmacy Intravenous Injection Immunoglobulin Product Portfolio
- 4.5.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
- 4.6 Hualan Bio
- 4.6.1 Hualan Bio Company Information
- 4.6.2 Hualan Bio Business Overview
- 4.6.3 Hualan Bio Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hualan Bio Intravenous Injection Immunoglobulin Product Portfolio
- 4.6.5 Hualan Bio Recent Developments
- 4.7 Nanyue Biopharming
- 4.7.1 Nanyue Biopharming Company Information
- 4.7.2 Nanyue Biopharming Business Overview
- 4.7.3 Nanyue Biopharming Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Nanyue Biopharming Intravenous Injection Immunoglobulin Product Portfolio
- 4.7.5 Nanyue Biopharming Recent Developments
- 4.8 Shanghai RAAS
- 4.8.1 Shanghai RAAS Company Information
- 4.8.2 Shanghai RAAS Business Overview
- 4.8.3 Shanghai RAAS Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shanghai RAAS Intravenous Injection Immunoglobulin Product Portfolio
- 4.8.5 Shanghai RAAS Recent Developments
- 4.9 Weiguang Biological
- 4.9.1 Weiguang Biological Company Information
- 4.9.2 Weiguang Biological Business Overview
- 4.9.3 Weiguang Biological Intravenous Injection Immunoglobulin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Weiguang Biological Intravenous Injection Immunoglobulin Product Portfolio
- 4.9.5 Weiguang Biological Recent Developments
5 Global Intravenous Injection Immunoglobulin Market Scenario by Region
- 5.1 Global Intravenous Injection Immunoglobulin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Intravenous Injection Immunoglobulin Sales by Region: 2021-2032
- 5.2.1 Global Intravenous Injection Immunoglobulin Sales by Region: 2021-2026
- 5.2.2 Global Intravenous Injection Immunoglobulin Sales by Region: 2027-2032
- 5.3 Global Intravenous Injection Immunoglobulin Revenue by Region: 2021-2032
- 5.3.1 Global Intravenous Injection Immunoglobulin Revenue by Region: 2021-2026
- 5.3.2 Global Intravenous Injection Immunoglobulin Revenue by Region: 2027-2032
- 5.4 North America Intravenous Injection Immunoglobulin Market Facts & Figures by Country
- 5.4.1 North America Intravenous Injection Immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Intravenous Injection Immunoglobulin Sales by Country (2021-2032)
- 5.4.3 North America Intravenous Injection Immunoglobulin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Intravenous Injection Immunoglobulin Market Facts & Figures by Country
- 5.5.1 Europe Intravenous Injection Immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Intravenous Injection Immunoglobulin Sales by Country (2021-2032)
- 5.5.3 Europe Intravenous Injection Immunoglobulin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Intravenous Injection Immunoglobulin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Intravenous Injection Immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Intravenous Injection Immunoglobulin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Intravenous Injection Immunoglobulin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Intravenous Injection Immunoglobulin Market Facts & Figures by Country
- 5.7.1 South America Intravenous Injection Immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Intravenous Injection Immunoglobulin Sales by Country (2021-2032)
- 5.7.3 South America Intravenous Injection Immunoglobulin Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Intravenous Injection Immunoglobulin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Intravenous Injection Immunoglobulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Intravenous Injection Immunoglobulin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Intravenous Injection Immunoglobulin Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Intravenous Injection Immunoglobulin Sales by Type (2021-2032)
- 6.1.1 Global Intravenous Injection Immunoglobulin Sales by Type (2021-2032) & (L)
- 6.1.2 Global Intravenous Injection Immunoglobulin Sales Market Share by Type (2021-2032)
- 6.2 Global Intravenous Injection Immunoglobulin Revenue by Type (2021-2032)
- 6.2.1 Global Intravenous Injection Immunoglobulin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Intravenous Injection Immunoglobulin Revenue Market Share by Type (2021-2032)
- 6.3 Global Intravenous Injection Immunoglobulin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Intravenous Injection Immunoglobulin Sales by Application (2021-2032)
- 7.1.1 Global Intravenous Injection Immunoglobulin Sales by Application (2021-2032) & (L)
- 7.1.2 Global Intravenous Injection Immunoglobulin Sales Market Share by Application (2021-2032)
- 7.2 Global Intravenous Injection Immunoglobulin Revenue by Application (2021-2032)
- 7.2.1 Global Intravenous Injection Immunoglobulin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Intravenous Injection Immunoglobulin Revenue Market Share by Application (2021-2032)
- 7.3 Global Intravenous Injection Immunoglobulin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Intravenous Injection Immunoglobulin Value Chain Analysis
- 8.1.1 Intravenous Injection Immunoglobulin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Intravenous Injection Immunoglobulin Production Mode & Process
- 8.2 Intravenous Injection Immunoglobulin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Intravenous Injection Immunoglobulin Distributors
- 8.2.3 Intravenous Injection Immunoglobulin Customers
9 Global Intravenous Injection Immunoglobulin Analyzing Market Dynamics
- 9.1 Intravenous Injection Immunoglobulin Industry Trends
- 9.2 Intravenous Injection Immunoglobulin Industry Drivers
- 9.3 Intravenous Injection Immunoglobulin Industry Opportunities and Challenges
- 9.4 Intravenous Injection Immunoglobulin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst